Dermata Therapeutics, Inc. DRMA

Set alert

Price alert · DRMA

All alert types
0.85 USD +0.10 +12.71%

As of Nov 3, 2:05 PM ET

Bid
0.83 × 2
Ask
0.85 × 1
0.7201 Day range 0.8499
0.603 52-week range 4.66
YTD
-63.38%
1 year
-75.16%
Open
0.7565
Prev close
0.7538
Mkt cap
4.21M
Vol
51.62K
Avg vol
3.44M
EPS
-4.39
P/E
0.00
Div yield
0.00%
More statistics
Low
0.7201
High
0.8499
Forward P/E
-0.32
Beta
0.79
Short ratio
0.52
Inst. own
0.66%
Dividend
0.00
Ex-div date
50-d avg
1.27
200-d avg
2.84
1y target
6.00

6M chart

Chart tools
Interval

Signals (33)
NameDateAgo
MACD: Buy SignalOct 28, 20266 days ago
RSI: OversoldOct 12, 20263 weeks ago
MACD: Sell SignalOct 9, 20263 weeks ago
MACD: Buy SignalOct 5, 20264 weeks ago
SMA: BearishSep 2, 20262 months ago
SMA: BearishAug 31, 20262 months ago
MACD: Sell SignalAug 31, 20262 months ago
SMA: BullishAug 12, 20262 months ago
SMA: BullishAug 12, 20262 months ago
MACD: Buy SignalAug 12, 20262 months ago
SMA: BearishJul 28, 20263 months ago
SMA: BearishJul 28, 20263 months ago
SMA: BullishJul 24, 20263 months ago
SMA: BullishJul 24, 20263 months ago
SMA: BearishJul 22, 20263 months ago
SMA: BearishJul 22, 20263 months ago
MACD: Sell SignalJul 15, 20263 months ago
SMA: BullishJun 26, 20264 months ago
MACD: Buy SignalJun 26, 20264 months ago
MACD: Sell SignalJun 25, 20264 months ago

Newest 20 of 33.

Analyst view

Price target (mean) 6.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy0
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 1

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

DRMA analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter0.000.00 – 0.000.000.0%00.0%0
Next quarter0.000.00 – 0.000.000.0%00.0%0
Current year0.000.00 – 0.000.000.0%00.0%0
Next year0.000.00 – 0.000.000.0%00.0%0

Upgrades and downgrades

The latest rating changes

DRMA analyst upgrades and downgrades
DateFirmActionFromTo
Aug 21, 2024Maxim GroupMaintainedBuyBuy
Mar 23, 2023Maxim GroupMaintained—Buy